Sage Therapeutics, Inc

AVEO Oncology is a Boston-based biopharmaceutical company dedicated to improving the lives of cancer patients through innovative medical solutions. As a subsidiary of LG Chem, the company focuses on developing and delivering effective treatments that address the unique challenges faced by individuals battling cancer. Committed to scientific advancement, AVEO's portfolio includes several promising therapies, such as FOTIVDA, Ficlatuzumab, and AV-380. The company's mission is driven by a passion for enhancing the quality of life for those affected by cancer, underscoring their focus on patient-centered care. Generated from the website

Vertex Pharmaceuticals Incorporated is a global biotechnology company engaged in the discovery and development of breakthrough small molecule drugs for serious diseases. The company commercializes its products independently and in collaboration with major pharmaceutical companies. Vertex s product line includes drugs for viral diseases, inflammation, autoimmune diseases and cancer. Vertex is developing treatments for cancer, HIV and AIDS and pain through collaborations with some of the leading pharmaceutical companies. The company has collaborations with Cystic Fibrosis Foundation Therapeutics, GlaxoSmithKline, Kissei Pharmaceutical, Merck & Co., Mitsubishi Pharma Corporation and Novartis Pharma. Vertex co-promotes the HIV and AIDS protease inhibitor, Lexiva, with GlaxoSmithKline. Vertex Pharmaceuticals Incorporated is located in Cambridge, Mass.

Lyra Therapeutics is a clinical-stage biotechnology company based in Watertown, MA, focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). With a commitment to addressing the needs of the 14 million individuals in the United States suffering from this debilitating condition, Lyra aims to provide long-lasting treatment options that break the cycle of relentless medical management. The company's lead product candidate, LYR210, features a bioabsorbable nasal mesh designed to deliver continuous anti-inflammatory medication directly to the sinonasal tissues for up to six months. By integrating advanced materials science with proven medication, Lyra Therapeutics is poised to transform the treatment landscape for CRS patients, offering a new solution for an often overlooked community. Generated from the website